Pfizer Seeks FDA Approval for Lyme Disease Vaccine with 70% Efficacy

Pfizer reported that its Lyme disease vaccine candidate demonstrated 70% efficacy in clinical trials. Despite this achievement, the vaccine missed a key statistical goal, which has raised concerns about its potential market impact. The company, along with its French partner Valneva, plans to pursue FDA approval even though low case numbers of Lyme disease contributed to the trial's challenges. This decision could signal significant developments in the vaccine market and impact future investor sentiment.